Allogene Therapeutics, Inc. — Director's Dealing 2021

Aug 3, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Allogene Therapeutics, Inc. (ALLO)
CIK: 0001737287
Period of Report: 2021-07-30

Reporting Person: SATO VICKI L (N/A)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$36.31	2030-09-16	Common Stock (3000)		Direct

Footnotes

F1: 50% of the shares subject to the stock option vested on October 31, 2020 and 50% of the shares subject to the stock option vested on February 28, 2021.